The glycogenolytic and hypertensive effect of physostigmine in the anti-nerve-growth-factor-serum-treated rats.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001923:Brain Chemistry; D002531:Cerebellum / Q000032:analysis; D002540:Cerebral Cortex / Q000032:analysis; D003964:Diaphragm / Q000187:drug effects; D005260:Female; D005725:Ganglia, Autonomic / Q000187:drug effects / Q000473:pathology; D006003:Glycogen / Q000032:analysis*; D006131:Growth Inhibitors; D007031:Hypothalamus / Q000032:analysis; D008099:Liver / Q000187:drug effects; D008112:Liver Glycogen / Q000032:analysis; D008297:Male; D008526:Medulla Oblongata / Q000032:analysis; D008636:Mesencephalon / Q000187:drug effects; D009206:Myocardium / Q000032:analysis; D009414:Nerve Growth Factors / Q000037:antagonists & inhibitors; D009417:Nerve Tissue / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects; D009929:Organ Size; D010830:Physostigmine / Q000494:pharmacology*; D051381:Rats
D006131:Growth Inhibitors; D008112:Liver Glycogen; D009414:Nerve Growth Factors; D006003:Glycogen; D010830:Physostigmine